ROIV
Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) has 16 SEC Form 4 filings (52 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is Director MANCHESTER KEITH S with 3 filings. Insiders have net sold $284.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Matthew Gline
- Employees:721
- HQ:London, GL, GB
- IPO:2020-12-08
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$352.9M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$24.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Fitzgerald MeghanFirst filing | Director | Sale | 10,000 | $349K | Jul 2 | SEC ↗ |
Epperly Melissa B,First filing | Director | Sale | 17,750 | $610K | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst filing | Director | Sale | 625,783 | $21.3M | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst filing | Director | Sale | 800,000 | $27.6M | Jul 1 | SEC ↗ |
MANCHESTER KEITH SFirst filing | Director | Sale | 212,380 | $7.5M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst filing | Director | Sale | 625,783 | $21.3M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst filing | Director | Sale | 800,000 | $27.6M | Jul 1 | SEC ↗ |
Gold Daniel AllenFirst filing | Director | Sale | 12,380 | $437K | Jul 1 | SEC ↗ |
QVT Financial LPFirst filing | Director by Deputization | Sale | 625,783 | $21.3M | Jun 30 | SEC ↗ |
QVT Financial LPFirst filing | Director by Deputization | Sale | 800,000 | $27.6M | Jun 30 | SEC ↗ |
QVT Financial LPFirst filing | Director by Deputization | Sale | 12,380 | $437K | Jun 30 | SEC ↗ |
Sukhatme MayukhFirst filing | President & CIO | Sale | 500,000 | $17.1M | Jun 29 | SEC ↗ |
Sukhatme MayukhFirst filing | President & CIO | Sale | 500,000 | $17.0M | Jun 29 | SEC ↗ |
| President & Immunovant CEO | Sale | 200,000 | $6.6M | Jun 26 | SEC ↗ | |
Venker EricFirst filing | President & Immunovant CEO | Sale | 200,000 | $6.1M | May 22 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 1,400,000 | $38.4M | Feb 23 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 1,012,610 | $27.5M | Feb 23 | SEC ↗ |
Torti FrankFirst filing | President and Vant Chair | Sale | 587,390 | $16.2M | Feb 23 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 774,142 | $16.8M | Dec 15 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 1,975,858 | $43.4M | Dec 15 | SEC ↗ |
Ramaswamy VivekFirst filing | 10% Owner | Sale | 353,745 | $7.8M | Dec 15 | SEC ↗ |
Related companies
Roivant Sciences Ltd. is in the Healthcare sector.